Astrazeneca Strategic Business Analysis
AstraZeneca
Strategic Business Analysis - Group Case Study
Case Abstract
Introduction AstraZeneca PLC (AstraZeneca, AZN:NYSE, AZN:LSE) is one of the largest pharmaceutical companies in the world. It was formed in 1999 from the merger of Sweden’s Astra AB and UK’s Zeneca Group plc. Core Activities AstraZeneca is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. One of the key benefits of the merger between Astra and Zeneca is seen as their portfolio of new products in development: AstraZeneca call this their 'product pipeline'. – Cardiovascular product pipeline includes Saxagliptin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca's Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune. Dapagliflozin,
– –
–
Products The company's product portfolio includes many world leaders and a number of high potential growth products: Arimidex (cancer), Crestor (cardiovascular), Nexium (gastrointestinal disease), Seroquel (schizophrenia) and Symbicort (asthma and chronic obstructive pulmonary disease). Profile – Active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US. It employs over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
–
Compiled by Rexford Sam
Group Case Study – Strategic Business Analysis (Re-Sit 2010)
1
– – –
Sales in 2008 totalled $31.6 billion. R&D investment totalled over $5 billion. It has around 12,000 people in our R&D organisation and 17
Strategic Business Analysis - Group Case Study
Case Abstract
Introduction AstraZeneca PLC (AstraZeneca, AZN:NYSE, AZN:LSE) is one of the largest pharmaceutical companies in the world. It was formed in 1999 from the merger of Sweden’s Astra AB and UK’s Zeneca Group plc. Core Activities AstraZeneca is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. One of the key benefits of the merger between Astra and Zeneca is seen as their portfolio of new products in development: AstraZeneca call this their 'product pipeline'. – Cardiovascular product pipeline includes Saxagliptin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca's Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune. Dapagliflozin,
– –
–
Products The company's product portfolio includes many world leaders and a number of high potential growth products: Arimidex (cancer), Crestor (cardiovascular), Nexium (gastrointestinal disease), Seroquel (schizophrenia) and Symbicort (asthma and chronic obstructive pulmonary disease). Profile – Active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US. It employs over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
–
Compiled by Rexford Sam
Group Case Study – Strategic Business Analysis (Re-Sit 2010)
1
– – –
Sales in 2008 totalled $31.6 billion. R&D investment totalled over $5 billion. It has around 12,000 people in our R&D organisation and 17
References: Compiled by Rexford Sam Group Case Study – Strategic Business Analysis (Re-Sit 2010) Compiled by Rexford Sam Group Case Study – Strategic Business Analysis (Re-Sit 2010) 9 E-version of annual reports Marks & Spencer, 2004. Annual report 2003-2004. [Online]. Available at: http://www-marks-andspencer.co.uk/corporate/annual2003/ [accessed 4 June 2005] Compiled by Rexford Sam Group Case Study – Strategic Business Analysis (Re-Sit 2010) 2